妊娠糖尿病における経口血糖降下薬とインスリンの比較:SUGAR-DIPランダム化比較試験に基づく社会的費用効果分析

Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost-Effectiveness Analysis of the SUGAR-DIP Randomized Controlled Trial

This study evaluates the societal cost-effectiveness of oral antihyperglycemic agents compared to insulin for gestational diabetes treatment, showing oral agents offer comparable benefits at potentially lower costs with small quality-adjusted life year gains.
奥希替尼联合萨沃替尼为晚期 EGFR 突变 NSCLC 合并 MET 异常患者带来生存获益

Enhanced Survival with Osimertinib and Savolitinib Combination in Advanced EGFR-Mutated NSCLC with MET Dysregulation Post-Osimertinib Progression

The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpression or amplification after osimertinib failure.